News

COVID-19: Proposals for achieving equitable global access for treatments, vaccines and diagnostics

The Access to COVID-19 Tools Accelerator (ACT-A) was launched by the World Health Organization (WHO), governments and global health actors as an ‘unprecedented and inclusive partnership’ to address some of the challenges linked with the management of the COVID-19 emergency and the development and delivery of needed treatments, vaccines and diagnostics. The partnership will need […]

Concrete actions needed for global pledges to result in access for all

Download the full statement Concrete actions needed for global pledges to result in access for all 4th May 2020 We welcome the efforts of the global health actors and other stakeholders to rally financial support to the research and development (R&D), manufacturing and distribution of COVID-19 vaccines, diagnostics and therapeutics through the May 4th global […]

COVID-19: Principles for Global Access, Innovation and Cooperation

The European Alliance for Respondible R&D and Affordable Medicines joined the international global health community to call on governments, agencies, manufacturers, donors and development partners to commit to global principles for access, innovation and access. The global effort is accompaigned by an online petition addressing European decision-makers in cooperation with WeMove.   COVID-19: Principles for […]

The fight against COVID-19: let’s make public investments count for people

On 25th March 2020, 62 organisations including patients, consumers, healthcare professionals, trade unions and public interest organisations published a letter to express our views on the importance of the role of public support to research and development during the current pandemic.  Since January, the European Commission and national governments have mobilised millions of Euros to […]

Public interest should be at the core of the future European Partnership on Innovative Health, say 43 organisations

Under the future Partnership between the European Commission and the healthcare sector industries, a considerable amount of public funds will be allocated to health research and innovation projects. 43 organisations including patients, consumers, doctors, payers, HTAs and public interest organisations express their views on the European Partnership on Innovative Health in a letter to the […]

Open letter supporting Italy’s proposed resolution on Improving the transparency of markets for drugs, vaccines and other health-related technologies

On February 1, 2019, the government of Italy submitted the text of draft resolution to the WHO, with a cover letter noting the aim of providing an “authoritative mandate to strengthen WHO’s technical work on the transparency of the costs of research and development and the transparency of prices” for discussion under agenda item 11.7 […]

Putting People’s Health First: Improving Access to Medicines in Europe

Putting People’s Health First: Improving Access to Medicines in Europe – November 2018 Download the European Elections Manifesto “Putting People’s Health First: Improving Access to Medicines in Europe” The Manifesto is also available in French, Spanish, Gaelic, Dutch, Greek Health and R&D policies are a critical to the success of the European project. In order to put […]

Civil society position on the proposal of the European Commission for the introduction of a Supplementary Protection Certificate (SPC) manufacturing waiver

Civil society position on the proposal of the European Commission for the introduction of a Supplementary Protection Certificate (SPC) manufacturing waiver As civil society organisations working on access to medicines and public health, we wish to contribute to the ongoing discussions on the European Commission proposal for the introduction of an SPC manufacturing waiver. European […]

Public Return on Public Investment: ensuring sustainable societal impact of EU-funded biomedical Research and Innovation

Civil society’s proposal for Horizon Europe, the next EU research framework programme Read and download the full proposal here September 2018 High prices of new drugs for cancer, hepatitis C and rare diseases in Europe have attracted great media and public attention and have brought the debate about access to medicines into the political spotlight […]

Ensuring EU funded medical R&I delivers for EU citizens and beyond

Civil society reaction to the European Commission’s proposal on Horizon Europe We, the undersigned twenty one civil society organisations, raise our strong concern about the European Commission proposal on the next research framework programme Horizon Europe which fails to make a serious commitment to ensure public interest-driven biomedical R&I. Though the challenge of access to […]